GlassScriptPhysician profile
Nathan C Mcbride
NPI 1114915741
$10,692.42
in general payments reported to CMS, 2019-2025
29 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,134 · 2022: $1,735 · 2023: $1,913 · 2024: $2,316 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,823.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,650.59 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,331.57 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,089.75 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $700.14 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Qol Medical, LLC | $534.31 | 2021-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $511.07 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $416.38 | 2021-2025 | |
| Pfizer INC. | $361.23 | 2023-2025 | |
| Genzyme Corporation | $358.05 | 2022-2025 | |
| Ardelyx, INC. | $320.47 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $317.95 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $308.76 | 2024-2025 | Zenpep, Vowst |
| Braintree Laboratories, INC. | $237.43 | 2021-2025 | Sutab, Suflave |
| Celgene Corporation | $201.70 | 2021-2024 | Zeposia |
| Celltrion USA INC. | $171.07 | 2025 | Vegzelma |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $171.03 | 2021-2025 | Hadlima |
| Phathom Pharmaceuticals, INC. | $166.92 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $160.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $138.69 | 2021-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $137.37 | 2021-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $82.09 | 2024-2025 | |
| Redhill Biopharma INC. | $67.12 | 2022 | |
| Lilly USA, LLC | $60.42 | 2023-2024 | Omvoh |
| Sandoz INC. | $47.57 | 2023-2024 | Hyrimoz |
| Shield Therapeutics INC | $39.40 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.81 | 2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $32.32 | 2023 | Idacio |
| Biocon Biologics INC | $22.89 | 2025 | Yesintek |
| Daiichi Sankyo INC. | $17.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.